|
|
*
96. Rossowski WJ, Zacharia S, Mungan Z, Ozmen V, Ertan A,
Baylor LM, Jiang NY, Coy D: Reduced gastric acid inhibitory effect
of pGlP(1-30)NH2 fragment with potent pancreatic amylase inhibitory
activity. Regulatory Peptides, 39:9-17, 1992. |
|
![]() |
* 98. Lopez J, Wright JA, Hammer, RA, Ertan
A: Chronic pancreatitis is associated with a high prevalence
of Giardiasis. Can J Gastroenterol,6(2):73-76, 1992. |
*100.
Hammer RA, Ochoa A, Fernandez C, Ertan A, Arimura A: Somatostatin
as a mediator of the effect of neurotensin on pentagastrin - stimulated
acid secretion in rats. Peptides, 13:1175-1179, 1992. *122. Younes M, Lechago J, Ertan A: Photodynamic therapy and genetic abnormalities. Gastroenterology, 120: 1065-6, 2001 (LTE). *123. Ertan A: Treatment of gallstones by extracorporeal shock wave lithotripsy. Am J Gastroenterol, 97: 831-2, 2002. *124. Dural TA, Ertan A: Endoscopic retrieval of proximally migrated dorsal pancreatic duct stent in a patient with pancreas divisium. Med Sci, 3:65-17, 2002 *125. Carlson N, Lechago J, Richter J, Sampliner RE, Peterson L, Santella RM, Goldsblum JR, Falk GW, Ertan A, Younes M: Acid supression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation. Am J Gastroenterol, 97: 1340 - 5, 2002. *126. Younes M, Henson DE, Ertan A, Miller CC: Incidence and survival trends of esophageal carcinoma in the United States. Racial and gender differences by histological type. Scand J Gastroenterol, 37:1359-65, 2002. *127. Liu L, Ergun G, Ertan A, et al: Detection of oxidative DNA damage in esophageal biopsies of patients with reflux symptoms and normal pH Monitoring. Aliment Pharmacol. Ther, 18: 693-8, 2003 *128. Younes M, Ertan A, Lechago J: p53 protein anad malignant progression in Barrett's metaplasia. Am J Gastroenterol, 95: 1200-1, 2003 (LTE). *129 Gonlusen, G., Akgun H, Ertan A, et al: Renal failure and nephrocalcinosis associated with oral phosphate bowel cleansing--Clinicial patterns and renal biopsy findings. Arch Pathol Lab Med, 129: 71-76, 2005. *130. Ertan A: Irritable bowel syndrome in women. Journal Watch Women' Health [the publisher of NEJM]. 10:68-9, 2005. *131. Peter MB, Obermeyer RJ, Ojeda HF …, Ertan A, et al: Laparascopic management of colon lipomas. JSLS, 9: 342-4, 2005. *132. Chen X, Lechago J, Ertan A, et al: Expression of the high mobility group proteins HMGI(Y) correlates with malignant progression in Barrett's metaplasia. Cancer Epidemiology, Biomarkers and Prevention, 13: 30-3, 2005. *133. Sanborn WJ, Colombel JF, Enns R, et al: Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med, 353: 1912-25, 2005 (Ertan A as a participating investigator). *134. Younes M, Ertan A, Ergun G, et al: Goblet cell mimickers in esophageal biopsies are not associated with an increased risk for dysplasia. Arch Path Lab Med, 131: 571-5, 2007. *135. Targan SR, Feagan BG, Fedorak RN, et al: Natalizumab for the treatment of active Crohn’s disease: Results of the ENCORE trial. Gastroenterology, 132: 1672-83, 2007 (Ertan A ,as a participating investigator). *136. Younes M, Ertan A, Ergun G, et al: Goblet cell mimickers in esophageal biopsies are not associated with an increased risk for dysplasia. Arch Pathol Lab Med. 131; 571-5, 2007. *137. Ertan A: Kemal Akdamar. Guncel Gastroenteroloji. 11:18-21, 2007. *138. Ergun GA, Ertan A: Non-surgical management of Barrett’s dysplasia. Houston Medical Journal. 11 & 21-4, 2008. *139. Younes M, Lauwers G, Ertan A, et al: The significance of indefinite for dysplasia grading in Barrett’s metaplasia. Modern Pathology, 132; 36-40, 2009. *140. Ertan A, Botoman VA: International gastroenterology and American College of Gastroenterology. Am J Gastroenterol, 2010 (in press). *141. Blackmon S, Zaheer I, Barrosso A, Ertan A: Photodynamic therapy versus radiofrequency ablation therapy in Barrett’s esophagus with dysplasia. Ann Surg, 2010 (submitted). *142. Lichtenstein GR, Thomsen O, Schreiber S, et al: Continous therapy with Certolizumab Pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gasterenterol Hepatol, 8; 600-9, 2010 (Ertan A as a participating investigator). *143. Younes M, Lauwers G, Ertan A, et al: The significance of indefinite for dysplasia grading in Barrett's metaplasia. Arch Pathol Lab Med, 135, 430-33, 2011. *144. Shaheen NJ, Bulsiewicz WJ, Lyday WD, Triadafilopoulos G, Wolfsen HC, Komanduri S, Chmielewski GW, Ertan A, et al: Prior fundoplication does not improve subsequent safety or efficacy outcomes of radiofrequency ablation (RFA): Results from the US RFA Registry. AJS, 2012 (Accepted). *145. Blackmon S, Zaheer I, Barroso A, Ertan A: Photodynamic therapy versus radiofrequency ablation therapy in Barrett’s esophagus with dysplasia. WJG, 2012 (submitted). *146. Villa N, El-Serag H, Younes M, Ertan A: Esophageal eosinophilia after radiofrequency ablation for Barrett’s esophagus. Esophagus, 2012 (submitted). Please download Dr. Ertan's CV for up-to-date publications.
|